LSE:BXP

Beximco Pharmaceuticals Limited · LSE · Healthcare · GBP · FY for 2024

Figures on this page computed 2026-11-08 12:47 UTC

Last close

n/aGBp

Market data

7.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
GBp
- computed
- Computed from the filing for 2024
12.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
- Computed from the filing for 2024
13.1%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
13.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
0.13Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
GBp
- Computed from the filing for 2024
- Computed from the filing for 2024
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
GBp
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

Follow one BDT

lens 1 of 9

After what it costs to make

44.2%

After running the business

19.5%

After interest and tax

13.1%

After what it must reinvest

13.8%

Kept after the dividend

10.2%

after what it costs to make, 44.2% of sales; after running the business, 19.5% of sales; after interest and tax, 13.1% of sales; after what it must reinvest, 13.8% of sales; kept after the dividend, 10.2% of sales

The five stops

5 of 5 read

After what it costs to make19,633,987,00044.2%
After running the business8,674,371,00019.5%
After interest and tax5,829,529,00013.1%
After what it must reinvest6,129,908,99413.8%
Kept after the dividend4,544,008,27210.2%

Of every unit of sales, 0.10 is still there after the dividend.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2024

Sales44,391,604,000
Source
computed
Statement
income
Fiscal year
2024
Reported in
BDT
After what it costs to make19,633,987,000
Source
computed
Statement
income
Fiscal year
2024
Reported in
BDT
After running the business8,674,371,000
Source
computed
Statement
income
Fiscal year
2024
Reported in
BDT
After interest and tax5,829,529,000
Source
computed
Statement
income
Fiscal year
2024
Reported in
BDT
After what it must reinvest6,129,908,994
Source
computed
Statement
income
Fiscal year
2024
Reported in
BDT
Kept after the dividend4,544,008,272
Source
computed
Statement
income
Fiscal year
2024
Reported in
BDT